Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics reported first quarter 2026 results and outlined next steps for its lead drug CAD-1005 in heparin-induced thrombocytopenia (HIT). Operating expenses fell to $2.5 million from $3.9 million a year earlier, narrowing the net loss to $2.5 million from $3.8 million.
As of March 31, 2026, the company held $2.3 million in cash and cash equivalents and later completed a $2.5 million financing to support near-term development. After receiving official End-of-Phase 2 FDA meeting minutes, Cadrenal plans a randomized, blinded, placebo-controlled Phase 3 registration trial of CAD-1005 added to standard care in HIT.
Cadrenal Therapeutics reported a Q1 2026 net loss of $2.5 million, narrower than $3.8 million a year earlier, as operating expenses fell 36% to $2.5 million. Cash and cash equivalents were $2.3 million with net cash used in operations of $3.0 million, raising substantial doubt about its ability to continue as a going concern.
The late-stage biopharma is prioritizing lead candidate CAD-1005 for heparin-induced thrombocytopenia and plans a Phase 3 trial targeting an NDA submission in 2029. Stockholders’ equity of $1.8 million fell below Nasdaq’s $2.5 million requirement, though a subsequent $2.5 million warrant exercise in April 2026 is expected to bolster equity.
Cadrenal Therapeutics announced that it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance for a pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia (HIT). Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The company plans a randomized, blinded, placebo-controlled Phase 3 study in approximately 120 HIT patients across up to 50 clinical centers worldwide, with treatment for up to 14 days during hospitalization. The trial is intended to support a projected NDA submission in 2029.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders, consisting of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The company will not receive proceeds from resales but will receive proceeds from any cash exercises of those warrants.
The registration fulfills contractual registration rights under an inducement agreement related to a private placement and warrants issued April 1, 2026; resales may occur in public or private transactions at prevailing or negotiated prices.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The resale proceeds will go to the selling stockholders; the company will receive proceeds only from any cash exercise of the warrants. The prospectus states 3,078,247 shares were outstanding as of April 1, 2026 and assumes 4,258,250 shares outstanding after full exercise.
Cadrenal Therapeutics, Inc. entered into a warrant inducement agreement with an existing holder, who agreed to exercise warrants for up to 571,430 common shares at $4.50 per share. This cash exercise is expected to provide approximately $2.5 million in gross proceeds for working capital.
In return, Cadrenal issued new unregistered Series B-1 and Series B-2 warrants, each for 571,430 shares at an exercise price of $4.50 per share, plus placement agent warrants for 37,143 shares at $5.625 per share. The company will file a Form S-3 to register the resale of the new warrant shares and agreed to short-term restrictions on issuing additional equity or registration statements.
Cadrenal Therapeutics registered 590,001 shares of Common Stock for resale under a prospectus supplement to its Form S-3 registration statement. The supplement states that 571,430 of those shares are issuable upon exercise of Existing Warrants that were amended on March 31, 2026 to reduce the exercise price from $16.50 to $4.50. The supplement covers resale "from time to time," and the prospectus remains qualified by the underlying Form S-3 prospectus.
The company reports a Nasdaq closing price of $5.12 per share as of March 31, 2026. The supplement updates warrant terms and registers the related shares; other prospectus terms continue to apply.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic conditions. The company has shifted its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), supported by orphan drug and Fast Track designations.
Cadrenal recently acquired a 12-LOX asset platform from Veralox and a portfolio of Factor XIa inhibitors, including frunexian, from eXIthera, adding clinical-stage assets and associated licenses and royalty obligations. Its broader pipeline includes tecarfarin, a late-stage vitamin K antagonist for high-risk cardiovascular patients, and frunexian, an IV Factor XIa inhibitor for acute critical-care settings.
On March 26, 2026, Cadrenal completed an End-of-Phase 2 FDA meeting for CAD-1005 and clarified a potential registrational path for a planned pivotal Phase 3 HIT trial, which remains subject to final FDA meeting minutes, protocol review and securing sufficient financing.